PFAM Search:   
       by Pfam accession/ID, keyword
QuickSearch:   
by PDB,NDB,UniProt,PROSITE Code or Search Term(s)  

Full view: branches of nodes matching the query are shown completely (Compact view)

(use 'Shift Left-Click' to collapse/expand all levels downwards; use 'Control Left-Click' to collapse/expand all levels upwards)
 
(-)
Clan: Peptidase_AA (368)
(-)
Family: Asp (155)
(-)
Blattella germanica (German cockroach) (Blatta germanica) (2)
2NR6B:13-325; B:13-325CRYSTAL STRUCTURE OF THE COMPLEX OF ANTIBODY AND THE ALLERGEN BLA G 2
3LIZA:13-325CRYSTAL STRUCTURE OF BLA G 2 COMPLEXED WITH FAB 4C3
(-)
Candida albicans (Yeast) (3)
2QZWB:13-330; B:13-330SECRETED ASPARTIC PROTEINASE (SAP) 1 FROM CANDIDA ALBICANS
1ZAPA:13-330SECRETED ASPARTIC PROTEASE FROM C. ALBICANS
2QZXB:13-330; B:13-330SECRETED ASPARTIC PROTEINASE (SAP) 5 FROM CANDIDA ALBICANS
(-)
Cryphonectria parasitica (Chesnut blight fungus) (Endothia parasitica) (6)
1OD1A:16-330ENDOTHIAPEPSIN PD135,040 COMPLEX
1OEWA:16-329ATOMIC RESOLUTION STRUCTURE OF NATIVE ENDOTHIAPEPSIN
1OEXA:16-329ATOMIC RESOLUTION STRUCTURE OF ENDOTHIAPEPSIN IN COMPLEX WITH A HYDROXYETHYLENE TRANSITION STATE ANALOGUE INHIBITOR H261
2JJIA:16-330ENDOTHIAPEPSIN IN COMPLEX WITH A GEM-DIOL INHIBITOR.
2V00A:16-330X-RAY CRYSTAL STRUCTURE OF ENDOTHIAPEPSIN COMPLEXED WITH COMPOUND 1
3LZYA:16-330CRYSTAL STRUCTURE OF ENDOTHIAPESIN IN COMPLEX WITH XENON
(-)
Homo sapiens (Human) (116)
1M4HB:13-357; B:13-357CRYSTAL STRUCTURE OF BETA-SECRETASE COMPLEXED WITH INHIBITOR OM00-3
1SGZD:13-357; D:13-357; D:13-357; D:13-357CRYSTAL STRUCTURE OF UNBOUND BETA-SECRETASE CATALYTIC DOMAIN.
1TQFA:13-357CRYSTAL STRUCTURE OF HUMAN BETA SECRETASE COMPLEXED WITH INHIBITOR
1W50A:13-357APO STRUCTURE OF BACE (BETA SECRETASE)
1W51A:13-357BACE (BETA SECRETASE) IN COMPLEX WITH A NANOMOLAR NON-PEPTIDIC INHIBITOR
1XN2D:13-357; D:13-357; D:13-357; D:13-357NEW SUBSTRATE BINDING POCKETS FOR BETA-SECRETASE.
1XN3D:13-357; D:13-357; D:13-357; D:13-357CRYSTAL STRUCTURE OF BETA-SECRETASE BOUND TO A LONG INHIBITOR WITH ADDITIONAL UPSTREAM RESIDUES.
1XS7D:13-357CRYSTAL STRUCTURE OF A CYCLOAMIDE-URETHANE-DERIVED NOVEL INHIBITOR BOUND TO HUMAN BRAIN MEMAPSIN 2 (BETA-SECRETASE).
1YM4C:13-357; C:13-357; C:13-357CRYSTAL STRUCTURE OF HUMAN BETA SECRETASE COMPLEXED WITH NVP-AMK640
2NTRA:13-357CRYSTAL STRUCTURE OF HUMAN BACE-1 BOUND TO INHIBITOR
2OAHA:13-357CRYSTAL STRUCTURE OF HUMAN BETA SECRETASE COMPLEXED WITH INHIBITOR
2OF0A:13-357X-RAY CRYSTAL STRUCTURE OF BETA SECRETASE COMPLEXED WITH COMPOUND 5
2OHKA:13-357X-RAY CRYSTAL STRUCTURE OF BETA SECRETASE COMPLEXED WITH 1-AMINO-ISOQUINOLINE
2OHMA:13-357X-RAY CRYSTAL STRUCTURE OF BETA SECRETASE COMPLEXED WITH N~3~-BENZYLPYRIDINE-2,3-DIAMINE
2OHNA:13-357X-RAY CRYSTAL STRUCTURE OF BETA SECRETASE COMPLEXED WITH 4-(4-FLUOROBENZYL)PIPERIDINE
2OHPA:13-357X-RAY CRYSTAL STRUCTURE OF BETA SECRETASE COMPLEXED WITH COMPOUND 3
2OHQA:13-357X-RAY CRYSTAL STRUCTURE OF BETA SECRETASE COMPLEXED WITH COMPOUND 4
2OHRA:13-357X-RAY CRYSTAL STRUCTURE OF BETA SECRETASE COMPLEXED WITH COMPOUND 6A
2OHSA:13-357X-RAY CRYSTAL STRUCTURE OF BETA SECRETASE COMPLEXED WITH COMPOUND 6B
2OHTA:13-357X-RAY CRYSTAL STRUCTURE OF BETA SECRETASE COMPLEXED WITH COMPOUND 7
2P4JD:13-357; D:13-357; D:13-357; D:13-357CRYSTAL STRUCTURE OF BETA-SECRETASE BOND TO AN INHIBITOR WITH ISOPHTHALAMIDE DERIVATIVES AT P2-P3
2P83C:13-357; C:13-357; C:13-357POTENT AND SELECTIVE ISOPHTHALAMIDE S2 HYDROXYETHYLAMINE INHIBITOR OF BACE1
2PH6A:13-357CRYSTAL STRUCTURE OF HUMAN BETA SECRETASE COMPLEXED WITH INHIBITOR
2PH8A:13-357CRYSTAL STRUCTURE OF HUMAN BETA SECRETASE COMPLEXED WITH INHIBITOR
2Q11C:13-357; C:13-357; C:13-357STRUCTURE OF BACE COMPLEXED TO COMPOUND 1
2Q15A:13-357STRUCTURE OF BACE COMPLEXED TO COMPOUND 3A
2QK5B:74-418; B:74-418STRUCTURE OF BACE1 BOUND TO SCH626485
2QMDB:74-418; B:74-418STRUCTURE OF BACE BOUND TO SCH722924
2QMFB:74-418; B:74-418STRUCTURE OF BACE BOUND TO SCH735310
2QMGB:74-418; B:74-418STRUCTURE OF BACE BOUND TO SCH745966
2QP8B:74-418; B:74-418STRUCTURE OF BACE BOUND TO SCH734723
2QU2A:75-419BACE1 WITH COMPOUND 1
2QU3A:75-419BACE1 WITH COMPOUND 2
2QZKA:13-357CRYSTAL STRUCTURE OF HUMAN BETA SECRETASE COMPLEXED WITH I21
2VA5A:13-357X-RAY CRYSTAL STRUCTURE OF BETA SECRETASE COMPLEXED WITH COMPOUND 8C
2VA6A:13-357X-RAY CRYSTAL STRUCTURE OF BETA SECRETASE COMPLEXED WITH COMPOUND 24
2VA7A:13-357X-RAY CRYSTAL STRUCTURE OF BETA SECRETASE COMPLEXED WITH COMPOUND 27
2VIEA:74-418HUMAN BACE-1 IN COMPLEX WITH N-((1S,2R)-1-BENZYL-2-HYDROXY-3-((1,1,5-TRIMETHYLHEXYL)AMINO)PROPYL)-3-(ETHYLAMINO)-5-(2-OXOPYRROLIDIN-1-YL)BENZAMIDE
2VIJA:74-418HUMAN BACE-1 IN COMPLEX WITH 3-(1,1-DIOXIDOTETRAHYDRO-2H-1, 2-THIAZIN-2-YL)-5-(ETHYLAMINO)-N-((1S,2R)-2-HYDROXY-1-( PHENYLMETHYL)-3-(1,2,3,4-TETRAHYDRO-1-NAPHTHALENYLAMINO) PROPYL)BENZAMIDE
2VIYA:74-418HUMAN BACE-1 IN COMPLEX WITH N-((1S,2R)-3-(((1S)-2-( CYCLOHEXYLAMINO)-1-METHYL-2-OXOETHYL)AMINO)-2-HYDROXY-1-( PHENYLMETHYL)PROPYL)-3-(PENTYLSULFONYL)BENZAMIDE
2VIZA:74-418HUMAN BACE-1 IN COMPLEX WITH N-((1S,2R)-3-(((1S)-2-( CYCLOHEXYLAMINO)-1-METHYL-2-OXOETHYL)AMINO)-2-HYDROXY-1-( PHENYLMETHYL)PROPYL)-3-(2-OXO-1-PYRROLIDINYL)-5-(PROPYLOXY) BENZAMIDE
2VJ6A:74-418HUMAN BACE-1 IN COMPLEX WITH N-((1S,2R)-3-(((1S)-2-( CYCLOHEXYLAMINO)-1-METHYL-2-OXOETHYL)AMINO)-2-HYDROXY-1-( PHENYLMETHYL)PROPYL)-3-(ETHYLAMINO)-5-(2-OXO-1-PYRROLIDINYL)BENZAMIDE
2VKMD:13-357; D:13-357; D:13-357; D:13-357CRYSTAL STRUCTURE OF GRL-8234 BOUND TO BACE (BETA-SECRETASE)
2VNMA:74-418HUMAN BACE-1 IN COMPLEX WITH 3-(1,1-DIOXIDOTETRAHYDRO-2H-1, 2-THIAZIN-2-YL)-5-(ETHYLAMINO)-N-((1S,2R)-2-HYDROXY-1-( PHENYLMETHYL)-3-(((3-(TRIFLUOROMETHYL)PHENYL)METHYL)AMINO) PROPYL)BENZAMIDE
2VNNA:74-418HUMAN BACE-1 IN COMPLEX WITH 7-ETHYL-N-((1S,2R)-2-HYDROXY-1-(PHENYLMETHYL)-3-(((3-(TRIFLUOROMETHYL)PHENYL)METHYL)AMINO) PROPYL)-1-METHYL-3,4-DIHYDRO-1H-(1,2,5)THIADIAZEPINO(3,4,5-HI)INDOLE-9-CARBOXAMIDE 2,2-DIOXIDE
2WF0A:74-418HUMAN BACE-1 IN COMPLEX WITH 4-ETHYL-N-((1S,2R)-2-HYDROXY-1-(PHENYLMETHYL)-3-(((3-(TRIFLUOROMETHYL)PHENYL)METHYL)AMINO) PROPYL)-8-(2-OXO-1-PYRROLIDINYL)-6-QUINOLINECARBOXAMIDE
2WF1A:74-418HUMAN BACE-1 IN COMPLEX WITH 7-ETHYL-N-((1S,2R)-2-HYDROXY-3-(((3-(METHYLOXY)PHENYL(METHYL)AMINO)-1-(PHENYLMETHYL) PROPYL)-1-METHYL-3,4-DIHYDRO-1H-(1,2,5)THIADIAZEPINO(3,4,5-HI)INDOLE-9-CARBOXAMIDE 2,2-DIOXIDE
2WF2A:74-418HUMAN BACE-1 IN COMPLEX WITH 8-ETHYL-N-((1S,2R)-2-HYDROXY-3-(((3-(METHYLOXY)PHENYL)METHYL)AMINO)-1-(PHENYLMETHYL) PROPYL)-1-METHYL-3,4,7,8-TETRAHYDRO-1H,6H-(1,2,5) THIADIAZEPINO(5,4,3-DE)QUINOXALINE-10-CARBOXAMIDE 2,2-DIOXIDE
2WF3A:74-418HUMAN BACE-1 IN COMPLEX WITH 6-(ETHYLAMINO)-N-((1S,2R)-2-HYDROXY-3-(((3-(METHYLOXY)PHENYL)METHYL)AMINO)-1-(PHENYLMETHYL)PROPYL)-1-METHYL-1, 3,4,5-TETRAHYDRO-2,1-BENZOTHIAZEPINE-8-CARBOXAMIDE 2,2-DIOXIDE
2WF4A:74-418HUMAN BACE-1 IN COMPLEX WITH 6-ETHYL-1-METHYL-N-((1S)-2-OXO-1-(PHENYLMETHYL)-3-(TETRAHYDRO-2H-PYRAN-4-YLAMINO)PROPYL)-1,3,4,6-TETRAHYDRO(1,2)THIAZEPINO(5,4,3-CD)INDOLE-8-CARBOXAMIDE 2,2-DIOXIDE
2WJOA:13-357HUMAN BACE (BETA SECRETASE) IN COMPLEX WITH CYCLOHEXANECARBOXYLIC ACID (2-(2-AM INO-6-PHENOXY-4H-QUINAZOLIN-3-YL)-2-CYCLOHEXYL-ETHYL)-AMIDE
2XFIA:74-418HUMAN BACE-1 IN COMPLEX WITH N-((1S,2R)-3-(((1S)-2-( CYCLOHEXYLAMINO)-1-METHYL-2-OXOETHYL)AMINO)-2-HYDROXY-1-( PHENYLMETHYL)PROPYL)-3-((METHYLSULFONYL)(PHENYL)AMINO) BENZAMIDE
2XFJA:74-418HUMAN BACE-1 IN COMPLEX WITH N-((1S,2R)-3-(((1S)-2-( CYCLOHEXYLAMINO)-1-METHYL-2-OXOETHYL)AMINO)-2-HYDROXY-1-( PHENYLMETHYL)PROPYL)-3-(ETHYLAMINO)-5-(2-OXO-1-PYRROLIDINYL)BENZAMIDE
2ZDZA:75-419X-RAY STRUCTURE OF BACE-1 IN COMPLEX WITH COMPOUND 3.B.10
2ZE1A:75-419X-RAY STRUCTURE OF BACE-1 IN COMPLEX WITH COMPOUND 6G
2ZHRB:13-357; B:13-357CRYSTAL STRUCTURE OF BACE1 IN COMPLEX WITH OM99-2 AT PH 5.0
2ZHSA:13-357CRYSTAL STRUCTURE OF BACE1 AT PH 4.0
2ZHTA:13-357CRYSTAL STRUCTURE OF BACE1 AT PH 4.5
2ZHUA:13-357CRYSTAL STRUCTURE OF BACE1 AT PH 5.0
2ZHVA:13-357CRYSTAL STRUCTURE OF BACE1 AT PH 7.0
2ZJHA:13-357CRYSTAL STRUCTURE OF THE HUMAN BACE1 CATALYTIC DOMAIN IN COMPLEX WITH N-(1-BENZYL-PIPERIDIN-4-YL)-4-MERCAPTO-BUTYRAMIDE
2ZJIA:13-357CRYSTAL STRUCTURE OF THE HUMAN BACE1 CATALYTIC DOMAIN IN COMPLEX WITH N-[1-(2,6-DIMETHOXY-BENZYL)-PIPERIDIN-4-YL]-4-MERCAPTO-BUTYRAMIDE
2ZJJA:13-357CRYSTAL STRUCTURE OF THE HUMAN BACE1 CATALYTIC DOMAIN IN COMPLEX WITH 4-(4-FLUORO-BENZYL)-PIPERAZINE-2-CARBOXYLIC ACID (2-MERCAPTO-ETHYL)-AMIDE
2ZJLA:13-357CRYSTAL STRUCTURE OF THE HUMAN BACE1 CATALYTIC DOMAIN IN COMPLEX WITH N-[1-(5-BROMO-2,3-DIMETHOXY-BENZYL)-PIPERIDIN-4-YL]-4-MERCAPTO-BUTYRAMIDE
2ZJMA:13-357CRYSTAL STRUCTURE OF THE HUMAN BACE1 CATALYTIC DOMAIN IN COMPLEX WITH N-[1-(5-CHLORO-2-ISOPROPOXY-3-METHOXY-BENZYL)-PIPERIDIN-4-YL]-2-(4-SULFAMOYL-PHENOXY)-ACETAMIDE
2ZJNA:13-357CRYSTAL STRUCTURE OF THE HUMAN BACE1 CATALYTIC DOMAIN IN COMPLEX WITH N-[1-(5-CHLORO-2-ISOPROPOXY-3-METHOXY-BENZYL)-PIPERIDIN-4-YL]-2-(2-METHYL-4-SULFAMOYL-PHENOXY)-ACETAMIDE
3K5CC:13-357; C:13-357; C:13-357HUMAN BACE-1 COMPLEX WITH NB-216
3K5DC:13-357; C:13-357; C:13-357CRYSTAL STRUCTURE OF BACE-1 IN COMPLEX WITH AHM178
3K5FC:13-357; C:13-357; C:13-357HUMAN BACE-1 COMPLEX WITH AYH011
3K5GC:13-357; C:13-357; C:13-357HUMAN BACE-1 COMPLEX WITH BJC060
3KMXB:74-418; B:74-418STRUCTURE OF BACE BOUND TO SCH346572
3KMYB:74-418; B:74-418STRUCTURE OF BACE BOUND TO SCH12472
3KN0B:74-418; B:74-418STRUCTURE OF BACE BOUND TO SCH708236
3KYRC:13-357; C:13-357; C:13-357BACE-1 IN COMPLEX WITH A NORSTATINE TYPE INHIBITOR
3L38A:75-419BACE1 IN COMPLEX WITH THE AMINOPYRIDINE COMPOUND 44
3L58B:74-418; B:74-418STRUCTURE OF BACE BOUND TO SCH589432
3L59B:74-418; B:74-418STRUCTURE OF BACE BOUND TO SCH710413
3L5BB:74-418; B:74-418STRUCTURE OF BACE BOUND TO SCH713601
3L5CB:74-418; B:74-418STRUCTURE OF BACE BOUND TO SCH723871
3L5DB:74-418; B:74-418STRUCTURE OF BACE BOUND TO SCH723873
3L5EB:74-418; B:74-418STRUCTURE OF BACE BOUND TO SCH736062
3L5FB:74-418; B:74-418STRUCTURE OF BACE BOUND TO SCH736201
3LHGA:75-419BACE1 IN COMPLEX WITH THE AMINOHYDANTOIN COMPOUND 4G
3LPIB:74-418; B:74-418STRUCTURE OF BACE BOUND TO SCH745132
3LPJB:74-418; B:74-418STRUCTURE OF BACE BOUND TO SCH743641
3LPKB:74-418; B:74-418STRUCTURE OF BACE BOUND TO SCH747123
3MSJC:13-357; C:13-357; C:13-357STRUCTURE OF BACE (BETA SECRETASE) IN COMPLEX WITH INHIBITOR
3MSKA:13-357FRAGMENT BASED DISCOVERY AND OPTIMISATION OF BACE-1 INHIBITORS
3MSLA:13-357FRAGMENT BASED DISCOVERY AND OPTIMISATION OF BACE-1 INHIBITORS
3N4LC:19-363; C:19-363; C:19-363BACE-1 IN COMPLEX WITH ELN380842
3NSHC:19-363; C:19-363; C:19-363BACE-1 IN COMPLEX WITH ELN475957
3OHFB:61-405; B:61-405CRYSTAL STRUCTURE OF BETA-SITE APP-CLEAVING ENZYME 1 (BACE-WT) COMPLEX WITH BMS-655295 AKA N~3~-((1S,2R)-1- BENZYL-2-HYDROXY-3-((3-METHOXYBENZYL)AMINO)PROPYL)-N~1~, N~1~-DIBUTYL-1H-INDOLE-1,3-DICARBOXAMIDE
3OHHB:61-405; B:61-405CRYSTAL STRUCTURE OF BETA-SITE APP-CLEAVING ENZYME 1 (BACE-WT) COMPLEX WITH BMS-681889 AKA N~1~-BUTYL-5-CYANO- N~3~-((1S,2R)-1-(3,5-DIFLUOROBENZYL)-2-HYDROXY-3-((3- METHOXYBENZYL)AMINO)PROPYL)-N~1~-METHYL-1H-INDOLE-1,3- DICARBOXAMIDE
3PI5C:13-357; C:13-357; C:13-357CRYSTAL STRUCTURE OF HUMAN BETA SECRETASE IN COMPLEX WITH BFG356
3QBHC:13-357; C:13-357; C:13-357STRUCTURE BASED DESIGN, SYNTHESIS AND SAR OF CYCLIC HYDROXYETHYLAMINE (HEA) BACE-1 INHIBITORS
3R1GB:74-418STRUCTURE BASIS OF ALLOSTERIC INHIBITION OF BACE1 BY AN EXOSITE-BINDING ANTIBODY
3S2OA:13-357FRAGMENT BASED DISCOVERY AND OPTIMISATION OF BACE-1 INHIBITORS
1LYAD:106-345; D:106-345; D:106-345; D:106-345CRYSTAL STRUCTURES OF NATIVE AND INHIBITED FORMS OF HUMAN CATHEPSIN D: IMPLICATIONS FOR LYSOSOMAL TARGETING AND DRUG DESIGN
1LYBD:106-345; D:106-345; D:106-345; D:106-345CRYSTAL STRUCTURES OF NATIVE AND INHIBITED FORMS OF HUMAN CATHEPSIN D: IMPLICATIONS FOR LYSOSOMAL TARGETING AND DRUG DESIGN
1LYWH:106-345; H:106-345; H:106-345; H:106-345; H:106-345; H:106-345; H:106-345; H:106-345CATHEPSIN D AT PH 7.5
1TZSA:24-341CRYSTAL STRUCTURE OF AN ACTIVATION INTERMEDIATE OF CATHEPSIN E
2RENA:19-339STRUCTURE OF RECOMBINANT HUMAN RENIN, A TARGET FOR CARDIOVASCULAR-ACTIVE DRUGS, AT 2.5 ANGSTROMS RESOLUTION
2V0ZO:13-325; O:13-325CRYSTAL STRUCTURE OF RENIN WITH INHIBITOR 10 (ALISKIREN)
2V10O:19-339; O:19-339CRYSTAL STRUCTURE OF RENIN WITH INHIBITOR 9
2V11O:19-339; O:19-339CRYSTAL STRUCTURE OF RENIN WITH INHIBITOR 6
2V12O:19-339; O:19-339CRYSTAL STRUCTURE OF RENIN WITH INHIBITOR 8
2V13A:19-339CRYSTAL STRUCTURE OF RENIN WITH INHIBITOR 7
2V16O:13-325; O:13-325CRYSTAL STRUCTURE OF RENIN WITH INHIBITOR 3
2X0BG:14-332; G:14-332; G:14-332; G:14-332CRYSTAL STRUCTURE OF HUMAN ANGIOTENSINOGEN COMPLEXED WITH RENIN
3O9LD:171-339; D:171-339; D:171-339; D:171-339DESIGN AND OPTIMISATION OF NEW PIPERIDINES AS RENIN INHIBITORS
3OADD:171-339; D:171-339; D:171-339; D:171-339DESIGN AND OPTIMIZATION OF NEW PIPERIDINES AS RENIN INHIBITORS
3OAGD:171-339; D:171-339; D:171-339; D:171-339DESIGN AND OPTIMIZATION OF NEW PIPERIDINES AS RENIN INHIBITORS
3OOTB:13-325; B:13-325CRYSTAL STRUCTURE ANALYSIS OF RENIN-INDOLE-PIPERAZIN INHIBITOR COMPLEXES
3OQFB:13-325; B:13-325CRYSTAL STRUCTURE ANALYSIS OF RENIN-INDOLE-PIPERAZINE INHIBITOR COMPLEXES
3OQKB:13-325; B:13-325CRYSTAL STRUCTURE ANALYSIS OF RENIN-INDOLE-PIPERAZIN INHIBITOR COMPLEXES
3OWNB:16-336; B:16-336POTENT MACROCYCLIC RENIN INHIBITORS
(-)
Hordeum vulgare (Barley) (1)
1QDMC:17-337; C:17-337; C:17-337CRYSTAL STRUCTURE OF PROPHYTEPSIN, A ZYMOGEN OF A BARLEY VACUOLAR ASPARTIC PROTEINASE.
(-)
Irpex lacteus (Milk-white toothed polypore) (Polyporus tulipiferae) (1)
1WKRA:13-332CRYSTAL STRUCTURE OF ASPARTIC PROTEINASE FROM IRPEX LACTEUS
(-)
Mus musculus (Mouse) (1)
1SMRG:13-325; G:13-325; G:13-325; G:13-325THE 3-D STRUCTURE OF MOUSE SUBMAXILLARY RENIN COMPLEXED WITH A DECAPEPTIDE INHIBITOR CH-66 BASED ON THE 4-16 FRAGMENT OF RAT ANGIOTENSINOGEN
(-)
Plasmodium falciparum (15)
3QRVB:13-325; B:13-325CRYSTAL STRUCTURE OF PLASMEPSIN I (PMI) FROM PLASMODIUM FALCIPARUM
3QS1D:13-325; D:13-325; D:13-325; D:13-325CRYSTAL STRUCTURE OF KNI-10006 COMPLEX OF PLASMEPSIN I (PMI) FROM PLASMODIUM FALCIPARUM
1LEEA:15-325CRYSTAL STRUCTURE OF PLASMEPSIN FROM P. FALCIPARUM IN COMPLEX WITH INHIBITOR RS367
1LF2A:15-325CRYSTAL STRUCTURE OF PLASMEPSIN II FROM P FALCIPARUM IN COMPLEX WITH INHIBITOR RS370
1LF3A:15-325CRYSTAL STRUCTURE OF PLASMEPSIN II FROM P FALCIPARUM IN COMPLEX WITH INHIBITOR EH58
1LF4A:15-325STRUCTURE OF PLASMEPSIN II
1M43B:15-325; B:15-325CRYSTAL STRUCTURE OF PMII IN COMPLEX WITH PEPSTATIN A TO 2.4 A
1ME6B:15-325; B:15-325CRYSTAL STRUCTURE OF PLASMEPSIN II, AN ASPARTYL PROTEASE FROM PLASMODIUM FALCIPARUM, IN COMPLEX WITH A STATINE-BASED INHIBITOR
1PFZD:15-325; D:15-325; D:15-325; D:15-325PROPLASMEPSIN II FROM PLASMODIUM FALCIPARUM
1SMEB:15-325; B:15-325PLASMEPSIN II, A HEMOGLOBIN-DEGRADING ENZYME FROM PLASMODIUM FALCIPARUM, IN COMPLEX WITH PEPSTATIN A
1W6HB:15-325; B:15-325NOVEL PLASMEPSIN II-INHIBITOR COMPLEX
1W6IC:15-325; C:15-325PLASMEPSIN II-PEPSTATIN A COMPLEX
1XDHB:15-325; B:15-325STRUCTURE OF PLASMEPSIN II IN COMPLEX WITH PEPSTATIN A
1XE6B:15-325; B:15-325STRUCTURE OF PLASMEPSIN II IN COMPLEX OF AN PEPSTATIN ANALOGUE
2R9BB:15-325; B:15-325STRUCTURAL ANALYSIS OF PLASMEPSIN 2 FROM PLASMODIUM FALCIPARUM COMPLEXED WITH A PEPTIDE-BASED INHIBITOR
(-)
Plasmodium vivax (1)
1MIQB:15-325; B:15-325CRYSTAL STRUCTURE OF PROPLASMEPSIN FROM THE HUMAN MALARIAL PATHOGEN PLASMODIUM VIVAX
(-)
Rhizomucor pusillus (1)
1MPPA:13-325X-RAY ANALYSES OF ASPARTIC PROTEINASES. V. STRUCTURE AND REFINEMENT AT 2.0 ANGSTROMS RESOLUTION OF THE ASPARTIC PROTEINASE FROM MUCOR PUSILLUS
(-)
Rhizopus chinensis (Bread mold) (3)
1UH7A:16-323CRYSTAL STRUCTURE OF RHIZOPUSPEPSIN AT PH 4.6
1UH8A:16-323CRYSTAL STRUCTURE OF RHIZOPUSPEPSIN AT PH 8.0
1UH9A:16-323CRYSTAL STRUCTURE OF RHIZOPUSPEPSIN AT PH 7.0
(-)
Saccharomyces cerevisiae (strain ATCC 204508 / S288c) (Bakers yeast) (1)
2JXRA:13-325STRUCTURE OF YEAST PROTEINASE A
(-)
Solanum tuberosum (Potato) (1)
3RFIA:1-103CRYSTAL STRUCTURE OF THE SAPOSIN-LIKE DOMAIN OF PLANT ASPARTIC PROTEASE FROM SOLANUM TUBEROSUM
(-)
Sus scrofa (Pig) (3)
1PSAB:13-325; B:13-325STRUCTURE OF A PEPSIN(SLASH)RENIN INHIBITOR COMPLEX REVEALS A NOVEL CRYSTAL PACKING INDUCED BY MINOR CHEMICAL ALTERATIONS IN THE INHIBITOR
1YX9A:13-326EFFECT OF DIMETHYL SULPHOXIDE ON THE CRYSTAL STRUCTURE OF PORCINE PEPSIN
3PEPA:13-325REVISED 2.3 ANGSTROMS STRUCTURE OF PORCINE PEPSIN. EVIDENCE FOR A FLEXIBLE SUBDOMAIN
(-)
Family: Asp_protease (1)
(-)
Homo sapiens (Human) (1)
3S8IB:242-343; B:242-343THE RETROVIRAL-LIKE PROTEASE (RVP) DOMAIN OF HUMAN DDI1
(-)
Family: RVP (212)
(-)
Avian myeloblastosis associated virus (MAV) (1)
1MVPB:6-122; B:6-122STRUCTURAL STUDIES OF THE RETROVIRAL PROTEINASE FROM AVIAN MYELOBLASTOSIS ASSOCIATED VIRUS
(-)
Feline immunodeficiency virus (isolate Petaluma) (FIV) (2)
3OGPB:9-115; B:9-115CRYSTAL STRUCTURE OF 6S-98S FIV PROTEASE WITH DARUNAVIR BOUND
3OGQB:9-115; B:9-115CRYSTAL STRUCTURE OF 6S-98S FIV PROTEASE WITH LOPINAVIR BOUND
(-)
Human T-lymphotropic virus 1 (6)
3LINL:6-114; L:6-114; L:6-114; L:6-114; L:6-114; L:6-114; L:6-114; L:6-114; L:6-114; L:6-114; L:6-114; L:6-114CRYSTAL STRUCTURE OF HTLV PROTEASE COMPLEXED WITH THE INHIBITOR, KNI-10562
3LIQB:6-114; B:6-114CRYSTAL STRUCTURE OF HTLV PROTEASE COMPLEXED WITH THE INHIBITOR, KNI-10673
3LITB:6-114; B:6-114THE CRYSTAL STRUCTURE OF HTLV PROTEASE COMPLEXED WITH THE INHIBITOR KNI-10681
3LIVB:6-114; B:6-114CRYSTAL STRUCTURE OF HTLV PROTEASE COMPLEXED WITH THE INHIBITOR KNI-10683
3LIXB:6-114; B:6-114CRYSTAL STRUCTURE OF HTLV PROTEASE COMPLEXED WITH THE INHIBITOR KNI-10729
3LIYF:6-114; F:6-114; F:6-114; F:6-114; F:6-114; F:6-114CRYSTAL STRUCTURE OF HTLV PROTEASE COMPLEXED WITH STATINE-CONTAINING PEPTIDE INHIBITOR
(-)
Human immunodeficiency virus 1 (23)
2RKFB:4-98; B:4-98HIV-1 PR RESISTANT MUTANT + LPV
2PC0A:1004-1098APO WILD-TYPE HIV PROTEASE IN THE OPEN CONFORMATION
2O40A:4-98CRYSTAL STRUCTURE OF A CHEMICALLY SYNTHESIZED 203 AMINO ACID 'COVALENT DIMER' HIV-1 PROTEASE MOLECULE
2PSUB:4-98; B:4-98CRYSTAL STRUCTURE OF WILD TYPE HIV-1 PROTEASE IN COMPLEX WITH CARB-AD37
2PSVB:4-98; B:4-98CRYSTAL STRUCTURE OF WILD TYPE HIV-1 PROTEASE IN COMPLEX WITH CARB-KB45
2Q54B:4-98; B:4-98CRYSTAL STRUCTURE OF KB73 BOUND TO HIV-1 PROTEASE
2Q55B:4-98; B:4-98CRYSTAL STRUCTURE OF KK44 BOUND TO HIV-1 PROTEASE
2Q5KB:4-98; B:4-98CRYSTAL STRUCTURE OF LOPINAVIR BOUND TO WILD TYPE HIV-1 PROTEASE
1RQ9B:4-98; B:4-98CRYSTAL STRUCTURES OF A MULTIDRUG-RESISTANT HIV-1 PROTEASE REVEAL AN EXPANDED ACTIVE SITE CAVITY
1TW7B:4-98; B:4-98WIDE OPEN 1.3A STRUCTURE OF A MULTI-DRUG RESISTANT HIV-1 PROTEASE REPRESENTS A NOVEL DRUG TARGET
3MWSB:104-198; B:104-198CRYSTAL STRUCTURE OF GROUP N HIV-1 PROTEASE
2P3AB:4-98; B:4-98CRYSTAL STRUCTURE OF THE MULTI-DRUG RESISTANT MUTANT SUBTYPE B HIV PROTEASE COMPLEXED WITH TL-3 INHIBITOR
2P3CB:4-98; B:4-98CRYSTAL STRUCTURE OF THE SUBTYPE F WILD TYPE HIV PROTEASE COMPLEXED WITH TL-3 INHIBITOR
2P3DB:4-98; B:4-98CRYSTAL STRUCTURE OF THE MULTI-DRUG RESISTANT MUTANT SUBTYPE F HIV PROTEASE COMPLEXED WITH TL-3 INHIBITOR
3OXCB:104-198; B:104-198WILD TYPE HIV-1 PROTEASE WITH ANTIVIRAL DRUG SAQUINAVIR
1WBKB:4-98; B:4-98HIV-1 PROTEASE IN COMPLEX WITH ASYMMETRIC INHIBITOR, BEA568
1WBMB:4-98; B:4-98HIV-1 PROTEASE IN COMPLEX WITH SYMMETRIC INHIBITOR, BEA450
1MUIB:4-98; B:4-98CRYSTAL STRUCTURE OF HIV-1 PROTEASE COMPLEXED WITH LOPINAVIR.
1OHRB:4-98; B:4-98VIRACEPT (R) (NELFINAVIR MESYLATE, AG1343): A POTENT ORALLY BIOAVAILABLE INHIBITOR OF HIV-1 PROTEASE
3LZUB:4-98; B:4-98CRYSTAL STRUCTURE OF A NELFINAVIR RESISTANT HIV-1 CRF01_AE PROTEASE VARIANT (N88S) IN COMPLEX WITH THE PROTEASE INHIBITOR DARUNAVIR.
1RPIB:4-98; B:4-98CRYSTAL STRUCTURES OF A MULTIDRUG-RESISTANT HIV-1 PROTEASE REVEAL AN EXPANDED ACTIVE SITE CAVITY
1RV7B:4-98; B:4-98CRYSTAL STRUCTURES OF A MULTIDRUG-RESISTANT HIV-1 PROTEASE REVEAL AN EXPANDED ACTIVE SITE CAVITY
3M9FB:4-98; B:4-98HIV PROTEASE COMPLEXED WITH COMPOUND 10B
(-)
Human immunodeficiency virus type 1 group M subtype A (isolate U455) (HIV-1) (1)
3LZSB:4-98; B:4-98CRYSTAL STRUCTURE OF HIV-1 CRF01_AE PROTEASE IN COMPLEX WITH DARUNAVIR
(-)
Human immunodeficiency virus type 1 group M subtype B (isolate ARV2/SF2) (HIV-1) (34)
1KJ4D:4-98; D:4-98; D:4-98; D:4-98SUBSTRATE SHAPE DETERMINES SPECIFICITY OF RECOGNITION RECOGNITION FOR HIV-1 PROTEASE: ANALYSIS OF CRYSTAL STRUCTURES OF SIX SUBSTRATE COMPLEXES
1KJ7B:4-98; B:4-98SUBSTRATE SHAPE DETERMINES SPECIFICITY OF RECOGNITION RECOGNITION FOR HIV-1 PROTEASE: ANALYSIS OF CRYSTAL STRUCTURES OF SIX SUBSTRATE COMPLEXES
1KJFB:4-98; B:4-98SUBSTRATE SHAPE DETERMINES SPECIFICITY OF RECOGNITION RECOGNITION FOR HIV-1 PROTEASE: ANALYSIS OF CRYSTAL STRUCTURES OF SIX SUBSTRATE COMPLEXES
1KJGB:4-98; B:4-98SUBSTRATE SHAPE DETERMINES SPECIFICITY OF RECOGNITION RECOGNITION FOR HIV-1 PROTEASE: ANALYSIS OF CRYSTAL STRUCTURES OF SIX SUBSTRATE COMPLEXES
1KJHB:4-98; B:4-98SUBSTRATE SHAPE DETERMINES SPECIFICITY OF RECOGNITION RECOGNITION FOR HIV-1 PROTEASE: ANALYSIS OF CRYSTAL STRUCTURES OF SIX SUBSTRATE COMPLEXES
1KZKB:4-98; B:4-98JE-2147-HIV PROTEASE COMPLEX
1MT7B:4-98; B:4-98VIABILITY OF A DRUG-RESISTANT HIV-1 PROTEASE MUTANT: STRUCTURAL INSIGHTS FOR BETTER ANTIVIRAL THERAPY
1MTBB:4-98; B:4-98VIABILITY OF A DRUG-RESISTANT HIV-1 PROTEASE MUTANT: STRUCTURAL INSIGHTS FOR BETTER ANTIVIRAL THERAPY
1MTRB:4-98; B:4-98HIV-1 PROTEASE COMPLEXED WITH A CYCLIC PHE-ILE-VAL PEPTIDOMIMETIC INHIBITOR
1N49D:4-98; D:4-98; D:4-98; D:4-98VIABILITY OF A DRUG-RESISTANT HIV-1 PROTEASE VARIANT: STRUCTURAL INSIGHTS FOR BETTER ANTI-VIRAL THERAPY
1T3RB:4-98; B:4-98HIV PROTEASE WILD-TYPE IN COMPLEX WITH TMC114 INHIBITOR
1TSQB:4-98; B:4-98CRYSTAL STRUCTURE OF AP2V SUBSTRATE VARIANT OF NC-P1 DECAMER PEPTIDE IN COMPLEX WITH V82A/D25N HIV-1 PROTEASE MUTANT
1TSUB:4-98; B:4-98CRYSTAL STRUCTURE OF DECAMER NCP1 SUBSTRATE PEPTIDE IN COMPLEX WITH WILD-TYPE D25N HIV-1 PROTEASE VARIANT
1YTGB:4-98; B:4-98SIV PROTEASE CRYSTALLIZED WITH PEPTIDE PRODUCT
1YTHB:4-98; B:4-98SIV PROTEASE CRYSTALLIZED WITH PEPTIDE PRODUCT
1Z1HB:104-198; B:104-198HIV-1 PROTEASE COMPLEXED WITH MACROCYCLIC PEPTIDOMIMETIC INHIBITOR 3
1Z1RB:104-198; B:104-198HIV-1 PROTEASE COMPLEXED WITH MACROCYCLIC PEPTIDOMIMETIC INHIBITOR 2
2JE4B:4-98; B:4-98ATOMIC-RESOLUTION CRYSTAL STRUCTURE OF CHEMICALLY-SYNTHESIZED HIV-1 PROTEASE IN COMPLEX WITH JG-365
2NXDB:4-98; B:4-98STRUCTURE OF HIV-1 PROTEASE D25N COMPLEXED WITH RT-RH ANALOGUE PEPTIDE GLY-ALA-ASP-ILE-PHE*TYR-LEU-ASP-GLY-ALA
2NXLB:4-98; B:4-98STRUCTURE OF HIV-1 PROTEASE D25N COMPLEXED WITH THE RT-RH ANALOGUE PEPTIDE GLY-ALA-GLU-VAL-PHE*TYR-VAL-ASP-GLY-ALA
2NXMB:4-98; B:4-98STRUCTURE OF HIV-1 PROTEASE D25N COMPLEXED WITH THE RT-RH ANALOGUE PEPTIDE GLY-ALA-GLN-THR-PHE*TYR-VAL-ASP-GLY-ALA
2Q3KB:4-98; B:4-98CRYSTAL STRUCTURE OF LYSINE SULFONAMIDE INHIBITOR REVEALS THE DISPLACEMENT OF THE CONSERVED FLAP WATER MOLECULE IN HIV-1 PROTEASE
2QHYB:4-98; B:4-98CRYSTAL STRUCTURE OF PROTEASE INHIBITOR, MIT-1-AC86 IN COMPLEX WITH WILD TYPE HIV-1 PROTEASE
2QHZB:4-98; B:4-98CRYSTAL STRUCTURE OF PROTEASE INHIBITOR, MIT-1-AC87 IN COMPLEX WITH WILD TYPE HIV-1 PROTEASE
2QI0B:4-98; B:4-98CRYSTAL STRUCTURE OF PROTEASE INHIBITOR, MIT-1-KK80 IN COMPLEX WITH WILD TYPE HIV-1 PROTEASE
2QI1B:4-98; B:4-98CRYSTAL STRUCTURE OF PROTEASE INHIBITOR, MIT-1-KK81 IN COMPLEX WITH WILD TYPE HIV-1 PROTEASE
2QI4B:4-98; B:4-98CRYSTAL STRUCTURE OF PROTEASE INHIBITOR, MIT-2-AD93 IN COMPLEX WITH WILD TYPE HIV-1 PROTEASE
2QI5B:4-98; B:4-98CRYSTAL STRUCTURE OF PROTEASE INHIBITOR, MIT-2-KC08 IN COMPLEX WITH WILD TYPE HIV-1 PROTEASE
2QI6B:4-98; B:4-98CRYSTAL STRUCTURE OF PROTEASE INHIBITOR, MIT-2-KB98 IN COMPLEX WITH WILD TYPE HIV-1 PROTEASE
2QI7B:4-98; B:4-98CRYSTAL STRUCTURE OF PROTEASE INHIBITOR, MIT-2-AD86 IN COMPLEX WITH WILD TYPE HIV-1 PROTEASE
3LZVB:4-98; B:4-98STRUCTURE OF NELFINAVIR-RESISTANT HIV-1 PROTEASE (D30N/N88D) IN COMPLEX WITH DARUNAVIR.
3MXDB:4-98; B:4-98CRYSTAL STRUCTURE OF HIV-1 PROTEASE INHIBITOR KC53 IN COMPLEX WITH WILD-TYPE PROTEASE
3MXEB:4-98; B:4-98CRYSTAL STRUCTURE OF HIV-1 PROTEASE INHIBITOR, KC32 COMPLEXED WITH WILD-TYPE PROTEASE
3OY4B:4-98; B:4-98CRYSTAL STRUCTURE OF HIV-1 L76V PROTEASE IN COMPLEX WITH THE PROTEASE INHIBITOR DARUNAVIR.
(-)
Human immunodeficiency virus type 1 group M subtype B (isolate BH10) (HIV-1) (27)
1MERB:4-98; B:4-98HIV-1 MUTANT (I84V) PROTEASE COMPLEXED WITH DMP450
1METB:4-98; B:4-98HIV-1 MUTANT (V82F) PROTEASE COMPLEXED WITH DMP323
1MEUB:4-98; B:4-98HIV-1 MUTANT (V82F, I84V) PROTEASE COMPLEXED WITH DMP323
1NPAB:4-98; B:4-98CRYSTAL STRUCTURE OF HIV-1 PROTEASE-HUP
1NPVB:204-298; B:204-298CRYSTAL STRUCTURE OF HIV-1 PROTEASE COMPLEXED WITH LDC271
1NPWB:204-298; B:204-298CRYSTAL STRUCTURE OF HIV PROTEASE COMPLEXED WITH LGZ479
1SBGB:4-98; B:4-98AN ORALLY-BIOAVAILABLE HIV-1 PROTEASE INHIBITOR CONTAINING AN IMIDAZOLE-DERIVED PEPTIDE BOND REPLACEMENT. CRYSTALLOGRAPHIC AND PHARMACOKINETIC ANALYSIS
1T7KB:4-98; B:4-98CRYSTAL STRUCTURE OF HIV PROTEASE COMPLEXED WITH ARYLSULFONAMIDE AZACYCLIC UREA
1W5VB:4-98; B:4-98HIV-1 PROTEASE IN COMPLEX WITH FLUORO SUBSTITUTED DIOL-BASED C2-SYMMETRIC INHIBITOR
1W5WB:4-98; B:4-98HIV-1 PROTEASE IN COMPLEX WITH FLUORO SUBSTITUTED DIOL-BASED C2-SYMMETRIC INHIBITOR
1W5XB:4-98; B:4-98HIV-1 PROTEASE IN COMPLEX WITH FLUORO SUBSTITUTED DIOL-BASED C2-SYMMETRIC INHIBITOR
1W5YB:4-98; B:4-98HIV-1 PROTEASE IN COMPLEX WITH FLUORO SUBSTITUTED DIOL-BASED C2-SYMMETRIC INHIBITOR
1YT9B:4-98; B:4-98HIV PROTEASE WITH OXIMINOARYLSULFONAMIDE BOUND
1ZP8A:4-98HIV PROTEASE WITH INHIBITOR AB-2
1ZPAA:4-98HIV PROTEASE WITH SCRIPPS AB-3 INHIBITOR
1ZSRB:104-198; B:104-198CRYSTAL STRUCTURE OF WILD TYPE HIV-1 PROTEASE (BRU ISOLATE) WITH A HYDROXYETHYLAMINE PEPTIDOMIMETIC INHIBITOR BOC-PHE-PSI[S-CH(OH) CH2NH]-PHE-GLU-PHE-NH2
2UXZB:104-198; B:104-198TWO-CARBON-ELONGATED HIV-1 PROTEASE INHIBITORS WITH A TERTIARY-ALCOHOL-CONTAINING TRANSITION-STATE MIMIC
2UY0B:104-198; B:104-198TWO-CARBON-ELONGATED HIV-1 PROTEASE INHIBITORS WITH A TERTIARY-ALCOHOL-CONTAINING TRANSITION-STATE MIMIC
3NU3B:104-198; B:104-198WILD TYPE HIV-1 PROTEASE WITH ANTIVIRAL DRUG AMPRENAVIR
3NU4B:104-198; B:104-198CRYSTAL STRUCTURE OF HIV-1 PROTEASE MUTANT V32I WITH ANTIVIRAL DRUG AMPRENAVIR
3NU5B:104-198; B:104-198CRYSTAL STRUCTURE OF HIV-1 PROTEASE MUTANT I50V WITH ANTIVIRAL DRUG AMPRENAVIR
3NU6B:4-98; B:4-98CRYSTAL STRUCTURE OF HIV-1 PROTEASE MUTANT I54M WITH ANTIVIRAL DRUG AMPRENAVIR
3NU9B:104-198; B:104-198CRYSTAL STRUCTURE OF HIV-1 PROTEASE MUTANT I84V WITH ANTIVIRAL DRUG AMPRENAVIR
3NUJB:4-98; B:4-98CRYSTAL STRUCTURE OF HIV-1 PROTEASE MUTANT I54V WITH ANTIVIRAL DRUG AMPRENAVIR
3NUOB:4-98; B:4-98CRYSTAL STRUCTURE OF HIV-1 PROTEASE MUTANT L90M WITH ANTIVIRAL DRUG AMPRENAVIR
3OK9B:104-198; B:104-198CRYSTAL STRUCTURE OF WILD-TYPE HIV-1 PROTEASE WITH NEW OXATRICYCLIC DESIGNED INHIBITOR GRL-0519A
3TLHA:4-98STRUCTURAL STUDIES OF HIV AND FIV PROTEASES COMPLEXED WITHAN EFFICIENT INHIBITOR OF FIV PR
(-)
Human immunodeficiency virus type 1 group M subtype B (isolate BH5) (HIV-1) (13)
1K1TB:104-198; B:104-198COMBINING MUTATIONS IN HIV-1 PROTEASE TO UNDERSTAND MECHANISMS OF RESISTANCE
1K1UB:104-198; B:104-198COMBINING MUTATIONS IN HIV-1 PROTEASE TO UNDERSTAND MECHANISMS OF RESISTANCE
1K2BB:4-98; B:4-98COMBINING MUTATIONS IN HIV-1 PROTEASE TO UNDERSTAND MECHANISMS OF RESISTANCE
1K2CB:4-98; B:4-98COMBINING MUTATIONS IN HIV-1 PROTEASE TO UNDERSTAND MECHANISMS OF RESISTANCE
1ODXB:4-98; B:4-98HIV-1 PROTEINASE MUTANT A71T, V82A
1Q9PA:4-94SOLUTION STRUCTURE OF THE MATURE HIV-1 PROTEASE MONOMER
1TCXB:4-98; B:4-98HIV TRIPLE MUTANT PROTEASE COMPLEXED WITH INHIBITOR SB203386
2NMYB:104-198; B:104-198CRYSTAL STRUCTURE ANALYSIS OF HIV-1 PROTEASE MUTANT V82A WITH A INHIBITOR SAQUINAVIR
2NMZB:104-198; B:104-198CRYSTAL STRUCTURE ANALYSIS OF HIV-1 PROTEASE MUTANT V82A WITH A INHIBITOR SAQUINAVIR
2NNKB:104-198; B:104-198CRYSTAL STRUCTURE ANALYSIS OF HIV-1 PROTEASE MUTANT I84V WITH A INHIBITOR SAQUINAVIR
2NNPB:104-198; B:104-198CRYSTAL STRUCTURE ANALYSIS OF HIV-1 PROTEASE MUTANT I84V WITH A INHIBITOR SAQUINAVIR
2R38B:4-98; B:4-98I84V HIV-1 PROTEASE MUTANT IN COMPLEX WITH A CARBAMOYL DECORATED PYRROLIDINE-BASED INHIBITOR
2R3TB:4-98; B:4-98I50V HIV-1 PROTEASE MUTANT IN COMPLEX WITH A CARBAMOYL DECORATED PYRROLIDINE-BASED INHIBITOR
(-)
Human immunodeficiency virus type 1 group M subtype B (isolate BRU/LAI) (HIV-1) (55)
1LZQB:104-198; B:104-198CRYSTAL STRUCTURE OF THE COMPLEX OF MUTANT HIV-1 PROTEASE (A71V, V82T, I84V) WITH AN ETHYLENAMINE PEPTIDOMIMETIC INHIBITOR BOC-PHE-PSI[CH2CH2NH]-PHE-GLU-PHE-NH2
1M0BB:104-198; B:104-198HIV-1 PROTEASE IN COMPLEX WITH AN ETHYLENEAMINE INHIBITOR
1MRWB:4-98; B:4-98STRUCTURE OF HIV PROTEASE (MUTANT Q7K L33I L63I) COMPLEXED WITH KNI-577
1MSMB:4-98; B:4-98THE HIV PROTEASE (MUTANT Q7K L33I L63I) COMPLEXED WITH KNI-764 (AN INHIBITOR)
1MSNB:4-98; B:4-98THE HIV PROTEASE (MUTANT Q7K L33I L63I V82F I84V) COMPLEXED WITH KNI-764 (AN INHIBITOR)
1NH0B:4-98; B:4-981.03 A STRUCTURE OF HIV-1 PROTEASE: INHIBITOR BINDING INSIDE AND OUTSIDE THE ACTIVE SITE
1RL8B:4-98; B:4-98CRYSTAL STRUCTURE OF THE COMPLEX OF RESISTANT STRAIN OF HIV-1 PROTEASE(V82A MUTANT) WITH RITONAVIR
1SDTB:104-198; B:104-198CRYSTAL STRUCTURES OF HIV PROTEASE V82A AND L90M MUTANTS REVEAL CHANGES IN INDINAVIR BINDING SITE.
1SDUB:104-198; B:104-198CRYSTAL STRUCTURES OF HIV PROTEASE V82A AND L90M MUTANTS REVEAL CHANGES IN INDINAVIR BINDING SITE.
1SDVB:104-198; B:104-198CRYSTAL STRUCTURES OF HIV PROTEASE V82A AND L90M MUTANTS REVEAL CHANGES IN INDINAVIR BINDING SITE.
1SGUB:4-98; B:4-98COMPARING THE ACCUMULATION OF ACTIVE SITE AND NON-ACTIVE SITE MUTATIONS IN THE HIV-1 PROTEASE
1SH9B:4-98; B:4-98COMPARING THE ACCUMULATION OF ACTIVE SITE AND NON-ACTIVE SITE MUTATIONS IN THE HIV-1 PROTEASE
1SP5B:4-98; B:4-98CRYSTAL STRUCTURE OF HIV-1 PROTEASE COMPLEXED WITH A PRODUCT OF AUTOPROTEOLYSIS
1U8GB:4-98; B:4-98CRYSTAL STRUCTURE OF A HIV-1 PROTEASE IN COMPLEX WITH PEPTIDOMIMETIC INHIBITOR KI2-PHE-GLU-GLU-NH2
1UPJA:4-98HIV-1 PROTEASE COMPLEX WITH U095438 [3-[1-(4-BROMOPHENYL) ISOBUTYL]-4-HYDROXYCOUMARIN
1XL2B:4-98; B:4-98HIV-1 PROTEASE IN COMPLEX WITH PYRROLIDINMETHANAMINE
1XL5B:4-98; B:4-98HIV-1 PROTEASE IN COMPLEX WITH AMIDHYROXYSULFONE
1Z8CB:104-198; B:104-198CRYSTAL STRUCTURE OF THE COMPLEX OF MUTANT HIV-1 PROTEASE (L63P, A71V, V82T, I84V) WITH A HYDROXYETHYLAMINE PEPTIDOMIMETIC INHIBITOR BOC-PHE-PSI[R-CH(OH)CH2NH]-PHE-GLU-PHE-NH2
1ZBGB:104-198; B:104-198CRYSTAL STRUCTURE OF A COMPLEX OF MUTANT HIV-1 PROTEASE (A71V, V82T, I84V) WITH A HYDROXYETHYLAMINE PEPTIDOMIMETIC INHIBITOR BOC-PHE-PSI[R-CH(OH)CH2NH]-PHE-GLU-PHE-NH2
1ZJ7A:4-98CRYSTAL STRUCTURE OF A COMPLEX OF MUTANT HIV-1 PROTEASE (A71V, V82T, I84V) WITH A HYDROXYETHYLAMINE PEPTIDOMIMETIC INHIBITOR BOC-PHE-PSI[S-CH(OH)CH2NH]-PHE-GLU-PHE-NH2
1ZLFB:104-198; B:104-198CRYSTAL STRUCTURE OF A COMPLEX OF MUTANT HIV-1 PROTEASE (A71V, V82T, I84V) WITH A HYDROXYETHYLAMINE PEPTIDOMIMETIC INHIBITOR
1ZPKB:104-198; B:104-198CRYSTAL STRUCTURE OF THE COMPLEX OF MUTANT HIV-1 PROTEASE (A71V, V82T, I84V) WITH A HYDROXYETHYLAMINE PEPTIDOMIMETIC INHIBITOR BOC-PHE-PSI[R-CH(OH)CH2NH]-PHE-GLU-PHE-NH2
1ZTZB:4-98; B:4-98CRYSTAL STRUCTURE OF HIV PROTEASE- METALLACARBORANE COMPLEX
2O4LB:4-98; B:4-98CRYSTAL STRUCTURE OF HIV-1 PROTEASE (Q7K, I50V) IN COMPLEX WITH TIPRANAVIR
2O4NB:4-98; B:4-98CRYSTAL STRUCTURE OF HIV-1 PROTEASE (TRM MUTANT) IN COMPLEX WITH TIPRANAVIR
2O4PB:4-98; B:4-98CRYSTAL STRUCTURE OF HIV-1 PROTEASE (Q7K) IN COMPLEX WITH TIPRANAVIR
2O4SB:4-98; B:4-98CRYSTAL STRUCTURE OF HIV-1 PROTEASE (Q7K) IN COMPLEX WITH LOPINAVIR
2P3BB:4-98; B:4-98CRYSTAL STRUCTURE OF THE SUBTYPE B WILD TYPE HIV PROTEASE COMPLEXED WITH TL-3 INHIBITOR
2PK5B:4-98; B:4-98CRYSTAL STRUCTURE OF HIV-1 PROTEASE (Q7K, L33I, L63I ) IN COMPLEX WITH KNI-10075
2PK6B:4-98; B:4-98CRYSTAL STRUCTURE OF HIV-1 PROTEASE (Q7K, L33I, L63I) IN COMPLEX WITH KNI-10033
2PQZB:4-98; B:4-98HIV-1 PROTEASE IN COMPLEX WITH A PYRROLIDINE-BASED INHIBITOR
2PWCB:4-98; B:4-98HIV-1 PROTEASE IN COMPLEX WITH A AMINO DECORATED PYRROLIDINE-BASED INHIBITOR
2PWRB:4-98; B:4-98HIV-1 PROTEASE IN COMPLEX WITH A CARBAMOYL DECORATED PYRROLIDINE-BASED INHIBITOR
2PYMB:4-98; B:4-98HIV-1 PR MUTANT IN COMPLEX WITH NELFINAVIR
2PYNB:4-98; B:4-98HIV-1 PR MUTANT IN COMPLEX WITH NELFINAVIR
2Q63B:4-98; B:4-98HIV-1 PR MUTANT IN COMPLEX WITH NELFINAVIR
2Q64B:4-98; B:4-98HIV-1 PR MUTANT IN COMPLEX WITH NELFINAVIR
2QAKB:4-98; B:4-98HIV-1 PR MUTANT IN COMPLEX WITH NELFINAVIR
2QCIB:104-198; B:104-198HIV-1 PROTEASE MUTANT D30N WITH POTENT ANTIVIRAL INHIBITOR GRL-98065
2QD7B:104-198; B:104-198HIV-1 PROTEASE MUTANT V82A WITH POTENT ANTIVIRAL INHIBITOR GRL-98065
2QHCB:4-98; B:4-98THE INFLUENCE OF I47A MUTATION ON REDUCED SUSCEPTIBILITY TO THE PROTEASE INHIBITOR LOPINAVIR
2QNNB:4-98; B:4-98HIV-1 PROTEASE IN COMPLEX WITH A MULTIPLE DECORATED PYRROLIDINE-BASED INHIBITOR
2QNQB:4-98; B:4-98HIV-1 PROTEASE IN COMPLEX WITH A CHLORO DECORATED PYRROLIDINE-BASED INHIBITOR
2R43B:4-98; B:4-98I50V HIV-1 PROTEASE IN COMPLEX WITH AN AMINO DECORATED PYRROLIDINE-BASED INHIBITOR
2UPJB:4-98; B:4-98HIV-1 PROTEASE COMPLEX WITH U100313 ([3-[[3-[CYCLOPROPYL [4-HYDROXY-2OXO-6-[1-(PHENYLMETHYL)PROPYL]-2H-PYRAN-3-YL] METHYL]PHENYL]AMINO]-3-OXO-PROPYL]CARBAMIC ACID TERT-BUTYL ESTER)
2Z4OB:104-198; B:104-198WILD TYPE HIV-1 PROTEASE WITH POTENT ANTIVIRAL INHIBITOR GRL-98065
2ZGAA:4-98HIV-1 PROTEASE IN COMPLEX WITH A DIMETHYLALLYL DECORATED PYRROLIDINE BASED INHIBITOR (HEXAGONAL SPACE GROUP)
2ZYEB:104-198; B:104-198STRUCTURE OF HIV-1 PROTEASE IN COMPLEX WITH POTENT INHIBITOR KNI-272 DETERMINED BY NEUTRON CRYSTALLOGRAPHY
3JVWB:104-198; B:104-198HIV-1 PROTEASE MUTANT G86A WITH SYMMETRIC INHIBITOR DMP323
3JW2B:104-198; B:104-198HIV-1 PROTEASE MUTANT G86S WITH DARUNAVIR
3KDBB:4-98; B:4-98CRYSTAL STRUCTURE OF HIV-1 PROTEASE (Q7K, L33I, L63I) IN COMPLEX WITH KNI-10006
3KDCB:4-98; B:4-98CRYSTAL STRUCTURE OF HIV-1 PROTEASE (Q7K, L33I, L63I) IN COMPLEX WITH KNI-10074
3KDDB:4-98; B:4-98CRYSTAL STRUCTURE OF HIV-1 PROTEASE (Q7K, L33I, L63I) IN COMPLEX WITH KNI-10265
3PWMB:104-198; B:104-198HIV-1 PROTEASE MUTANT L76V WITH DARUNAVIR
3PWRB:104-198; B:104-198HIV-1 PROTEASE MUTANT L76V COMPLEXED WITH SAQUINAVIR
(-)
Human immunodeficiency virus type 1 group M subtype B (isolate HXB2) (HIV-1) (12)
1LV1A:1004-1098CRYSTAL STRUCTURE ANALYSIS OF THE NON-ACTIVE SITE MUTANT OF TETHERED HIV-1 PROTEASE TO 2.1A RESOLUTION
1ODWB:4-98; B:4-98NATIVE HIV-1 PROTEINASE
1ODYB:4-98; B:4-98HIV-1 PROTEASE COMPLEXED WITH AN INHIBITOR LP-130
1QBRB:4-98; B:4-98HIV-1 PROTEASE INHIBITORS WIIH LOW NANOMOLAR POTENCY
1QBSB:4-98; B:4-98HIV-1 PROTEASE INHIBITORS WIIH LOW NANOMOLAR POTENCY
1QBUB:4-98; B:4-98HIV-1 PROTEASE INHIBITORS WIIH LOW NANOMOLAR POTENCY
2NPHB:1004-1098; B:1004-1098CRYSTAL STRUCTURE OF HIV1 PROTEASE IN SITU PRODUCT COMPLEX
2WHHA:4-98HIV-1 PROTEASE TETHERED DIMER Q-PRODUCT COMPLEX ALONG WITH NUCLEOPHILIC WATER MOLECULE
3KT2A:4-98CRYSTAL STRUCTURE OF N88D MUTANT HIV-1 PROTEASE
3KT5A:1004-1098CRYSTAL STRUCTURE OF N88S MUTANT HIV-1 PROTEASE
3MIMB:1004-1098; B:1004-1098X-RAY SNAPSHOT OF HIV-1 PROTEASE IN ACTION: OBSERVATION OF TETRAHEDRAL INTERMEDIATE AND ITS SIHB WITH CATALYTIC ASPARTATE
3N3IA:4-98CRYSTAL STRUCTURE OF G48V/C95F TETHERED HIV-1 PROTEASE/SAQUINAVIR COMPLEX
(-)
Human immunodeficiency virus type 1 group M subtype B (isolate YU-2) (HIV-1) (18)
1K6CB:4-98; B:4-98LACK OF SYNERGY FOR INHIBITORS TARGETING A MULTI-DRUG RESISTANT HIV-1 PROTEASE
1K6PB:4-98; B:4-98LACK OF SYNERGY FOR INHIBITORS TARGETING A MULTI-DRUG RESISTANT HIV-1 PROTEASE
1K6TB:4-98; B:4-98LACK OF SYNERGY FOR INHIBITORS TARGETING A MULTI-DRUG RESISTANT HIV-1 PROTEASE
1K6VB:4-98; B:4-98LACK OF SYNERGY FOR INHIBITORS TARGETING A MULTI-DRUG RESISTANT HIV-1 PROTEASE
1T7JB:4-98; B:4-98CRYSTAL STRUCTURE OF INHIBITOR AMPRENAVIR IN COMPLEX WITH A MULTI-DRUG RESISTANT VARIANT OF HIV-1 PROTEASE (L63P/V82T/I84V)
3OQ7A:4-98CRYSTAL STRUCTURES OF MULTIDRUG-RESISTANT CLINICAL ISOLATE 769 HIV-1 PROTEASE VARIANTS
3OQAA:4-98CRYSTAL STRUCTURES OF MULTIDRUG-RESISTANT CLINICAL ISOLATE 769 HIV-1 PROTEASE VARIANTS
3OQDA:4-98CRYSTAL STRUCTURES OF MULTIDRUG-RESISTANT CLINICAL ISOLATE 769 HIV-1 PROTEASE VARIANTS
3OTSB:4-98; B:4-98MDR769 HIV-1 PROTEASE COMPLEXED WITH MA/CA HEPTA-PEPTIDE
3OTYB:4-98; B:4-98MDR769 HIV-1 PROTEASE COMPLEXED WITH RT/RH HEPTA-PEPTIDE
3OU1B:4-98; B:4-98MDR769 HIV-1 PROTEASE COMPLEXED WITH RH/IN HEPTA-PEPTIDE
3OU3B:4-98; B:4-98MDR769 HIV-1 PROTEASE COMPLEXED WITH PR/RT HEPTA-PEPTIDE
3OU4B:4-98; B:4-98MDR769 HIV-1 PROTEASE COMPLEXED WITH TF/PR HEPTA-PEPTIDE
3OUAB:4-98; B:4-98MDR769 HIV-1 PROTEASE COMPLEXED WITH P1/P6 HEPTA-PEPTIDE
3OUBB:4-98; B:4-98MDR769 HIV-1 PROTEASE COMPLEXED WITH NC/P1 HEPTA-PEPTIDE
3OUCB:4-98; B:4-98MDR769 HIV-1 PROTEASE COMPLEXED WITH P2/NC HEPTA-PEPTIDE
3OUDB:4-98; B:4-98MDR769 HIV-1 PROTEASE COMPLEXED WITH CA/P2 HEPTA-PEPTIDE
3PJ6A:4-98CRYSTAL STRUCTURES OF MULTIDRUG-RESISTANT CLINICAL ISOLATE 769 HIV-1 PROTEASE VARIANTS
(-)
Human immunodeficiency virus type 1 group M subtype C (isolate 92BR025) (HIV-1) (2)
2R5QD:4-98; D:4-98; D:4-98; D:4-98CRYSTAL STRUCTURE ANALYSIS OF HIV-1 SUBTYPE C PROTEASE COMPLEXED WITH NELFINAVIR
2R8NA:4-98STRUCTURAL ANALYSIS OF THE UNBOUND FORM OF HIV-1 SUBTYPE C PROTEASE
(-)
Human immunodeficiency virus type 1 group M subtype D (isolate Z2/CDC-Z34) (HIV-1) (10)
1PROB:4-98; B:4-98HIV-1 PROTEASE DIMER COMPLEXED WITH A-98881
1VIJB:4-98; B:4-98HIV-1 PROTEASE COMPLEXED WITH THE INHIBITOR HOE/BAY 793 HEXAGONAL FORM
1VIKB:4-98; B:4-98HIV-1 PROTEASE COMPLEXED WITH THE INHIBITOR HOE/BAY 793 ORTHORHOMBIC FORM
2WKZB:104-198; B:104-198HIV-1 PROTEASE INHIBITORS CONTAINING A TERTIARY ALCOHOL IN THE TRANSITION-STATE MIMIC WITH IMPROVED CELL-BASED ANTIVIRAL ACTIVITY
2WL0B:104-198; B:104-198HIV-1 PROTEASE INHIBITORS CONTAINING A TERTIARY ALCOHOL IN THE TRANSITION-STATE MIMIC WITH IMPROVED CELL-BASED ANTIVIRAL ACTIVITY
3KF0B:4-98; B:4-98HIV PROTEASE WITH FRAGMENT 4D9 BOUND
3KFNB:4-98; B:4-98HIV PROTEASE (PR) WITH INHIBITOR TL-3 AND FRAGMENT HIT 4D9 BY SOAKING
3KFPA:4-98HIV PROTEASE (PR) WITH INHIBITOR TL-3 BOUND, AND DMSOS IN EXO SITE
3KFRB:4-98; B:4-98HIV PROTEASE (PR) DIMER WITH INHIBITOR TL-3 BOUND AND FRAGMENT 1F1 IN THE OUTSIDE/TOP OF FLAP
3KFSB:4-98; B:4-98HIV PROTEASE (PR) DIMER WITH INHIBITOR TL-3 BOUND AND FRAGMENT 2F4 IN THE OUTSIDE/TOP OF FLAP
(-)
Human immunodeficiency virus type 2 subtype A (isolate ROD) (HIV-2) (2)
1JLDB:4-98; B:4-98POTENT HIV PROTEASE INHIBITORS CONTAINING A NOVEL (HYDROXYETHYL)AMIDE ISOSTERE
2MIPD:4-98; D:4-98; D:4-98; D:4-98CRYSTAL STRUCTURE OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) TYPE 2 PROTEASE IN COMPLEX WITH A REDUCED AMIDE INHIBITOR AND COMPARISON WITH HIV-1 PROTEASE STRUCTURES
(-)
Rous sarcoma virus (strain Prague C) (RSV-PrC) (1)
2RSPB:6-122; B:6-122STRUCTURE OF THE ASPARTIC PROTEASE FROM ROUS SARCOMA RETROVIRUS REFINED AT 2 ANGSTROMS RESOLUTION
(-)
Simian immunodeficiency virus (isolate Mm142-83) (SIV-mac) (Simian immunodeficiency virus rhesus mon (4)
1SIVB:4-98; B:4-98THREE-DIMENSIONAL STRUCTURE OF A SIV PROTEASE(SLASH)INHIBITOR COMPLEX. IMPLICATIONS FOR THE DESIGN OF HIV-1 AND HIV-2 PROTEASE INHIBITORS
1TCWB:4-98; B:4-98SIV PROTEASE COMPLEXED WITH INHIBITOR SB203386
1YTIA:4-98SIV PROTEASE CRYSTALLIZED WITH PEPTIDE PRODUCT
1YTJA:4-98SIV PROTEASE CRYSTALLIZED WITH PEPTIDE PRODUCT
(-)
Xenotropic MuLV-related virus (isolate VP62) (XMRV) (1)
3NR6B:12-106; B:12-106CRYSTAL STRUCTURE OF XENOTROPIC MURINE LEUKEMIA VIRUS-RELATED VIRUS (XMRV) PROTEASE